Quote from: KarmaGirl on December 01, 2016, 03:44:52 PM
Here's my issue. I'm borderline Hypertension. I'm going on a Low salt diet as well. I'm taking it in pills.
If you are taking bio-identical estradiol (estradiol, estradiol valerate), this shouldn't be a concern, according to studies. Spironolactone is an anti-androgen that can reduce blood pressure, bio-identical progesterone can also help with this.
Ann Clin Res. 1983;15 Suppl 38:1-121.
Blood pressure and hemodynamics in postmenopausal women during estradiol-17 beta substitution."Estradiol-17 beta substitution decreased the systolic and diastolic blood pressure in normotensive, hypertensive and borderline hypertensive postmenopausal women.
The blood pressure of the hypertensive subjects decreased on average more than the blood pressure of the normotensive subjects."
"Irrespective of the pretreatment blood pressure levels, heart rate decreased during estradiol-17 beta substitution"
"Estradiol-17 beta substitution caused an increase in the blood volume in all groups of postmenopausal women"
"Cardiac output increased in the normotensive test subjects but decreased in the hypertensive and borderline hypertensive subjects"
Horm Mol Biol Clin Investig. 2014 May;18(2):89-103."The cardiovascular protection observed in females has been attributed to the beneficial effects of estrogen on endothelial function."
"estrogen alone or combined with progesterone has been associated with decreased blood pressure"
Climacteric. 2013 Apr;16(2):265-73."Estradiol decreased systolic blood pressure, plasma aldosterone levels, and the expression of renal sodium transporters."
Hypertension. 1999 May;33(5):1190-4."Fifteen healthy postmenopausal women were studied in each of 3 conditions: on placebo, after 8 weeks of transdermal estradiol (...) twice per week, and again 2 weeks after addition of intravaginal progesterone"
"Levels of estrogen and progesterone similar to those in premenopausal women were achieved. On estradiol, nocturnal systolic BP (110+/-3 mm Hg), diastolic BP (63+/-2 mm Hg), and mean BP (77+/-2 mm Hg) fell significantly (P<0.02) compared with placebo systolic BP (116+/-2 mm Hg), diastolic BP (68+/-2 mm Hg), and mean BP (82+/-2 mm Hg). Daytime BP followed the same trend but was significantly lower only for mean BP. There was no activation of the RAAS. The addition of progesterone resulted in no further fall in BP but a significant activation of the RAAS.
Thus, contrary to what is often assumed, administration of estradiol with or without progesterone not only did not raise BP but rather substantially lowered BP. This BP-lowering effect may be responsible for the lower incidence of hypertension in premenopausal than in postmenopausal women."
BMJ. 2012 Oct 9; 345"In this randomised trial including 1006 women we found
a significantly decreased risk of the composite endpoint of death, heart failure, or myocardial infarction when hormone replacement therapy was started early in postmenopause. The beneficial effect occurred in the 10 years randomisation phase and was maintained for an additional six years of non-randomised follow-up. The trend for all components of the endpoint was in the same direction (figs 3 to 6) and this finding was not associated with an increased risk of cancer, stroke, deep vein thrombosis, or pulmonary embolism. Thus this study implies that hormone therapy started in recently menopausal women and continued for a prolonged duration does not increase or provoke adverse cardiovascular events such as mortality, stroke, heart failure, or myocardial infarction."
Obstet Gynecol. 2015 Mar;125(3):605-10."
In transgender women, estrogen therapy, with or without antiandrogen therapy, was associated with lower BP."
"Transgender women were treated with estrogens. Fourteen (88%) were given sublingual micronized 17-beta estradiol (....) twice daily. One subject was given (...) estradiol via transdermal patch, and one subject received estradiol valerate (...) intramuscular every 2 weeks.
All but one transgender woman (who wished to retain erectile function) were administered spironolactone"
"All transgender women had estradiol levels at least in the physiologic female – range at 6 months, with 3/16 (19%) having supraphysiologic levels > 1000pg/dl (including the one transgender woman using intramuscular estradiol valerate)."
Should read pg/
ml (typo).
"Transgender women (persons assigned male at birth, but who identify as females and who use estrogens with or without an anti-androgen to develop female secondary sex characteristics) had normal median baseline and 6 month body mass index (24.8 kg/m2 (IQR=4.3) and 23 kg/m2 (IQR=4.5) respectively).
Both systolic and diastolic median blood pressures in this group dropped significantly from baseline to 6 months (130.5 mmHg (IQR 11.5) to 120.5 mmHg (IQR 15.5) p=.006; 78 mmHg (IQR 21) to 67 mmHg (IQR 12), p=.001 respectively)."
Menopause. 2014 Jan 6."Rylance et al39: Results of this small, double-blind, placebo-controlled, cross-over study showed that
the use of orally administered natural progesterone caused a significant reduction in BP in individuals with mild to moderate HTN who were not using any other antihypertensive medications »
Br Med J (Clin Res Ed). 1985 Jan 5;290(6461):13-4."In a placebo controlled, double blind crossover study natural progesterone was given by mouth, in increasing doses, to six men and four postmenopausal women with mild to moderate hypertension who were not receiving any other antihypertensive drugs. When compared with values recorded before treatment and during administration of placebo progesterone caused a significant reduction in blood pressure,
suggesting that progesterone has an antihypertensive action rather than a hypertensive one as has been previously thought. This possible protective effect of progesterone should be investigated further."
Climacteric. 2013 Aug;16 Suppl 1:44-53."in the PEPI trial43, an increase in blood pressure occurred after 1 year in all CEE + MPA regimens but not in those receiving CEE + micronized progesterone.
The addition of micronized progesterone to CEE has been reported to abolish the increased daytime blood pressure of normotensive women and potentiate the CEE-related decreased daytime systolic blood pressure in hypertensive women26."
MPA and CEE are non bio-identical forms of progestins and estrogens, they can have an adverse effect.
Endocrine Reviews, April 2013, 34(2):171–208"Interestingly, no changes were observed in blood pressure with progesterone administration to normotensive postmenopausal women, although
a slight reduction in blood pressure was observed in hypertensive women (198)."
My levels of estradiol are between 1,000-4,000 pg/ml, women's levels during pregnancy are as high as 75,000 pg/ml (1,000-75,000), levels in the range of 400-700 pg/ml in men with prostate cancer (49-91 yrs old) given estradiol non-orally with no cardiovascular complications and improved lipid profiles. I take oral progesterone as well. My blood pressure is fine, I'm under the supervision of three doctors.
Br J Obstet Gynaecol. 1990 Oct;97(10):917-21."There is some anxiety about the possible harmful sequelae of supraphysiological estradiol levels but
no data are currently available to show any deleterious effects of these levels on coagulation factors, blood pressure, glucose tolerance or the occurrences of endometrial or breast cancer (Hammond et al. 1974; Thom et id. 1978; Studd B Thom 1981; Armstrong 1988)."
"Supraphysiological oestradiol levels are an uncommon consequence of oestradiol implants (...).
These high serum oestradiol levels were not associated with any deleterious effects and may be necessary for the control of symptoms in specific women"
"The mean serum oestradiol level of the 1388 women attending the clinic in 1988 was 767 pmol/l (range
78-2925 pmol/l), 66% had serum oestradiol levels <1000 pmol/l and 3% (38 women) had levels >1750 pmol/l (Fig 1)."
"The 15 women with PMS had a mean serum oestradiol of 2209 pmol/l (range 1760-2820 pmol/l). Their mean age at the start of treatment was 40 years (range 34-54) and the mean duration of therapy was 5.5 years (range 1-12)."
"The 23 menopausal women had a mean serum oestradiol of 2015 pmol/l (range 1785-2925 pmol/l). Their mean age was 46 years (range 29-58) and the mean duration of therapy was 4.5 years (range 1-10)."
pmol/L to pg/ml: divide by 3.671
Lowering carbohydrates has also shown to have a positive impact on blood pressure as the lower insulin is, the less there is sodium (and water retention).
Am J Physiol Heart Circ Physiol. 2013 Jun 15;304(12):H1733-42. (in hypertensive rats)
"In conclusion,
a low-carbohydrate/high-fat diet reduced blood pressure and improved arterial function in SHR without producing signs of insulin resistance or altering insulin-mediated signaling in the heart, skeletal muscle, or vasculature."
Nutr Res. 2013 Nov;33(11):905-12."In conclusion, these findings demonstrate that individuals undergoing statin therapy experience
additional improvements in metabolic and vascular health from a 6 weeks CRD as evidenced by increased insulin sensitivity and resistance vessel endothelial function, and decreased blood pressure, triglycerides, and adhesion molecules."
CRD = carbohydrate restricted diet
Arch Intern Med. 2010;170(2):136-145."Two potent weight loss therapies, a low-carbohydrate, ketogenic diet (LCKD) and orlistat therapy combined with a low-fat diet (O + LFD), are available to the public but, to our knowledge, have never been compared."
"In a sample of medical outpatients, an LCKD led to similar improvements as O + LFD for weight, serum lipid, and glycemic parameters and
was more effective for lowering blood pressure. »
I believe having a doctor who encourages feedback and involvement from the patient is great.

Best of luck.